Emerging treatment options for patients with castration-resistant prostate cancer

Prostate

Volumn 72, Issue 3, 2012, Pages 338-349

  George, Daniel ^a   Moul, Judd W ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

androgen independent prostate cancer; progression; resistance; targeted agent

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ATRASENTAN; CABAZITAXEL; DASATINIB; DENOSUMAB; ENDOTHELIN RECEPTOR ANTAGONIST; IPILIMUMAB; ORTERONEL; RADIUM 223; TASQUINIMOD; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; ZIBOTENTAN;

ANDROGEN SYNTHESIS; ARTICLE; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT;

CLINICAL TRIALS AS TOPIC; DRUG THERAPY; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84855669062     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21435     Document Type: Article

References (51)

1. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS,. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 2918-2925. (Pubitemid 46224110)
2. Devlin HL, Mudryj M,. Progression of prostate cancer: Multiple pathways to androgen independence. Cancer Lett 2009; 274: 177-186.
3. Niu YN, Xia SJ,. Stroma-epithelium crosstalk in prostate cancer. Asian J Androl 2009; 11: 28-35.
4. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL,. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005; 11: 4653-4657. (Pubitemid 41557182)
5. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP,. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-2825.
6. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS,. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-4571.
7. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ,. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28: 1481-1488.
8. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS,. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-1495.
9. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS,. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-3748.
10. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI,. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-1501.
11. de Bono JS, Logothetis CJ, Fizazi K, North S, Chu L, Chi KN, Kheoh T, Haqq C, Molina A, Scher HI, on behalf of the COU-AA-301 Investigators. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (PTS) with metastatic castration-resistant prostate cancer (MCRPC) who have progressed after docetaxel-based chemotherapy (CHEMO): Results of COU-AA-301, a randomized, double-blind, placebo-controlled phase III study [abstract]. Ann Oncol 2010; 21: viii3. Abstract LBA5.
12. Study of Investigational Agent Abiraterone Acetate for Metastatic Advanced Prostate Cancer Unblinded After Meeting Pre-Determined Criteria. http://www.jnj.com/connect/news/product/Study-of-Investigational-Agent- Abiraterone-Acetate-for-Metastatic-Advanced-Prostate-Cancer-Unblinded-After- Meeting-Pre-Determined-Criteria, Accessed March 9, 2011.
13. Dreicer R, Agus DB, MacVicar GR, MacLean D, Zhang T, Stadler WM,. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: A phase I/II, open-label study. Abstract presented at: 2010 Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA.
14. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL,. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790.
15. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL,. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010; 375: 1437-1446.
16. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, Kantoff PW,. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932-1936. (Pubitemid 32994827)
17. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J,. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-409. (Pubitemid 24058195)
18. Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL,. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 2070-2076.
19. Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM, Morris MJ, Kantoff PW, Monk JP, Small EJ,. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401 [abstract]. J Clin Oncol 2010; 28: Abstract LBA4511.
20. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS,. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393-11398. (Pubitemid 34920936)
21. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR, Tew WP,. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010; 28: 207-214.
22. Tew WP, Gordon M, Murren J, Dupont J, Pezzulli S, Aghajanian C, Sabbatini P, Mendelson D, Schwartz L, Gettinger S, Psyrri A, Cedarbaum JM, Spriggs DR,. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 2010; 16: 358-366.
23. Olsson A, Bjork A, Vallon-Christersson J, Isaacs JT, Leanderson T,. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 2010; 9: 107.
24. Bratt O, Haggman M, Ahlgren G, Nordle O, Bjork A, Damber JE,. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer 2009; 101: 1233-1240.
25. Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Forsberg G, Carducci MA, Armstrong AJ,. A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer (CRPC) [abstract]. J Clin Oncol 2010; 28: Abstract 4510.
26. Bagnato A, Rosano L,. The endothelin axis in cancer. Int J Biochem Cell Biol 2008; 40: 1443-1451.
27. Chi KN, Bjartell A, Dearnaley D, Saad F, Schroder FH, Sternberg C, Tombal B, Visakorpi T,. Castration-resistant prostate cancer: From new pathophysiology to new treatment targets. Eur Urol 2009; 56: 594-605.
28. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB,. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110: 1959-1966. (Pubitemid 350036854)
29. Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, Qian J, Steinberg J, Carducci M,. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113: 2478-2487.
30. Warren R, Liu G,. ZD4054: A specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Invest Drugs 2008; 17: 1237-1245.
31. James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA,. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: A double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55: 1112-1123.
32. Dawson NA, Growcott JW, Morris T, Phung DH, James ND,. Zibotentan (ZD4054): A specific endothelin-A receptor antagonist with potential for the treatment of castrate-resistant prostate cancer. Poster presented at: Society of Urologic Oncology's 10 Annual Meeting in Conjunction with the World Urological Oncology Federation; December 3-4, 2009; Bethesda, MD.
33. Results of Zibotentan Phase III trial in castration resistant prostate cancer. http://www.astrazeneca.com/Media/Pressreleases/Article/Results-of- Zibotentan-Phase-III-trial-incastration-resistant-pr. Accessed March 9, 2011.
34. AstraZeneca halts phase III trial of ZIBOTENTAN in non-metastatic castrate resistant prostate cancer. http://www.astrazeneca.com/Media/Press- releases/Article/0022011AstraZeneca-halts-phase-III-trial-of-ZIBOTENTAN. Accessed March 9, 2011.
35. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabro F, Cheng S, Trudel GC, Paliwal P, Sternberg CN,. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15: 7421-7428.
36. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R,. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185-9189. (Pubitemid 41507982)
37. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM,. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-3094. (Pubitemid 46638945)
38. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW,. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-3679.
39. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frolich MW, Schellhammer PF, for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
40. Dipaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K, Schuetz T,. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 2006; 4: 1.
41. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR,. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1099-1105.
42. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP,. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007; 13: 1810-1815. (Pubitemid 46952950)
43. Tollefson MK, Karnes RJ, Thompson RH, Granberg CF, Hillman DW, Breau RH, Allison JP, Blute ML, Kwon ED,. A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer. Abstract presented at: The American Society of Clinical Oncology Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA.
44. Smith MR, Egerdie B, Hernandez TN, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C,. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-755.
45. Fizazi K, Carducci MA, Smith MR, Damião R, Brown JE, Karsh L, Milecki P, Wang H, Dansey RD, Goessl CD,. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer [abstract]. J Clin Oncol 2010; 28: Abstract LBA4507.
46. Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, Forouzesh B, Beeram M, Patnaik A, Molpus K, Semiond D, Besenval M, Tolcher AW,. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 723-730.
47. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376: 1147-1154.
48. Jevtana® (cabazitaxel) Injection Approved by U.S. FDA After Priority Review. http://sanofi-aventis.mediaroom.com/index.php?-43-288. Accessed March 9, 2011.
49. Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernas B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS,. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8: 587-594. (Pubitemid 46995621)
50. Nilsson S, Parker C, Haugen I, Lokna A, Aksnes A, Bolstad B, O'Bryan-Tear G, Bruland OS,. Radium-223 chloride, a first-in-class alpha-pharmaceutical with a benign safety profile for patients with castration resistant prostate cancer (CRPC) and bone metastases: Combined analysis of phase I and II clinical trials [abstract]. J Clin Oncol 2010; 28: Abstract 4678.
51. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ,. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-1237. (Pubitemid 46606398)